Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I

Details Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I

1991-02-04

1994-06-21

Hill, Jr., Robert J.

Drug, bio-affecting and body treating compositions

Extract, body fluid, or cellular material of undetermined...

Blood

424115, 530395, 435 724, A61K 3514, A61K 3722

Patent

active

053226992

ABSTRACT:
The invention is concerned with the discovery, isolation and purification of an agent or factor named herein the CR3 modulator or CMF-1 that is synthesized by polymorphonuclear leukocytes (PMN) in response to agonists which enhance CD18 activity. The CR3 modulator binds to CD18 and activates its adhesion-promoting ability. The CR3 modulator appears to be transiently produced by PMN as an acidic amphiphilic lipid. The CR3 modulator can be assayed by adding dilutions of a CR3 modulator -containing solution to resting PMN and observing the ability of CR3 to mediate binding of erythrocytes coated with C3bi (EC3bi). The isolation of the CR3 modulator, its biological and physical properties and diagnostic and therapeutic uses are described.

REFERENCES:
patent: 4684623 (1987-08-01), Larrick et al.
patent: 4686100 (1987-08-01), Raffin et al.
patent: 4794277 (1989-01-01), Arford et al.
patent: 4840793 (1989-06-01), Todd, III et al.
patent: 4935234 (1990-06-01), Todd, III et al.
Rosso et al., J. Exp. Pathol. 3(1):425-7 (1989).
Smyth et al., J. Biol. Chem. 267:15568-77 (1992).
Wright et al., J. Immunol. 136:1759-64 (1986).
Schleiffenbaum et al., J. Immunol. 142:3537-45 (1989).
Philips et al., J. Clin. Invest. 82:495-501 (1988).
Dransfield, Chem. Immunol. 50:13-33 (1991).
Hermanowski-Vosatka, A., et al. (1992) Cell 68:341-52.
Lehninger, A. L., Biochemistry, 2nd ed., pp. 379-380. New York: Worth, 1975.
Wright et al., Proc. Natl. Acad. Sci. USA, 80, pp. 5699-5703 (1983).
Tuomanen et al., J. Infect. Dis., 151, pp. 535-540 (1985).
Quagliarello et al., J. Clin. Invest., 77, pp. 1084-1095 (1986).
Arfors et al., Blood, 69, pp. 338-340 (1987).
Ismail et al., Blood, 69, pp. 1167-1174 (1987).
Price et al., J. Immunology, 139, pp. 4174-4177 (1987).
Quazliarello et al., Abstracts of the 1987 ICAAC, p. 204 (1987).
Rosen et al., J. Exp. Med., 166, pp. 1685-1701 (1987).
Sande et al., Ped. Infec. Dis. J., 6, pp. 1143-1171 (1987).
Tuomanen et al., J. Infect. Dis., 155, pp. 985-990 (1987).
Tuomanen et al., Am. Rev. Respir. Dis., 135, pp. 869-874 (1987).
Ripley-Petzoldt et al., J. Infect. Dis., 157, pp. 245-255 (1988).
Simpson et al., J. Clin. Invest., 81, pp. 624-629 (1988).
Tauber et al., J. Infect. Dis., 157, pp. 456-464 (1988).
Wright et al., Proc. Natl. Acad. Sci. USA, 85, pp. 7734-7738 (1988).
Lo et al., J. Exp. Med., 169, pp. 1779-1793 (1989).
Tuomanen et al., J. Exp. Med., 170, pp. 959-968 (1989).
Tuomanen et al., Ped. Inf. Dis. J., 8(12), pp. 924-928 (1989).
Fischer et al., Lancet, Nov. 8, pp. 1058-1061 (1986).
Honn, K., et al., "Lipoxygenase Products Regulate IRGpllb/lla Receptor Mediated Adhesion Of Tumor Cells To Endothelial Cells, Subendothelial Matrix And Fibronectin", Proc. Soc. Exp. Biol. Med., 189:130-135 (1988).
Hass, Thomas A., et al., "Binding Of 13-Hode and 5-, 12- and 15-Hete To Endothelial Cells And Subsequent Platelet, Neutrophil And Tumor Cell Adhesion", Biochimica et Biophysica Acta., 961:153-159 (1988).

Affiliated with

Also associated with

Rating

Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leukocyte-derived CR3 modulator, integrin modulating factor-1 (I will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2219528